(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.34%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.48%.
Oric Pharmaceuticals's earnings in 2026 is -$135,214,000.On average, 18 Wall Street analysts forecast ORIC's earnings for 2026 to be -$152,967,901, with the lowest ORIC earnings forecast at -$168,402,370, and the highest ORIC earnings forecast at -$141,301,472. On average, 17 Wall Street analysts forecast ORIC's earnings for 2027 to be -$165,400,361, with the lowest ORIC earnings forecast at -$188,691,812, and the highest ORIC earnings forecast at -$130,432,128.
In 2028, ORIC is forecast to generate -$177,491,212 in earnings, with the lowest earnings forecast at -$205,937,838 and the highest earnings forecast at -$111,954,243.